By MICHAEL J. de la MERCED and ANDREW POLLACK
AbbVie agreed to pay $5.8 billion to acquire Stemcentrx as it continues its big push into cancer treatment.
Published: April 29, 2016 at 12:00AM
from NYT Business Day http://ift.tt/1WsGjyn
from WordPress http://ift.tt/1SMFJJa
via Hadi Aboukhater
No comments:
Post a Comment